UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

UNBURDENING THE PILL LOAD: REAL-WORLD EVIDENCE OF MEDICATION REDUCTION AFTER ENDOSCOPIC SLEEVE GASTROPLASTY

Yan Ling Ong 1, Michael Chu 1, Sushmitha C 1, Charlene Tan 1, Tian Yu Qiu 1, Carlos Paolo Francisco 2, Rajesh R 3, Ravishankar Asokkumar 4

Affiliations

1 Singapore General Hospital, Singapore, Singapore

2 St. Luke's Medical Center - Global City, Taguig City, Philippines

3 Duke-NUS Graduate Medical School, Singapore, Singapore|||Singapore General Hospital, Singapore, Singapore

4 Singapore General Hospital, Singapore, Singapore|||Duke-NUS Graduate Medical School, Singapore, Singapore

Summary

AI Generated

Endoscopic Sleeve Gastroplasty in 236 patients was associated with significant reductions in medication burden for obesity-related comorbidities at 6 and 12 months post-procedure.

Mean medication count for diabetes, hypertension, and hyperlipidemia decreased from 1.36 at baseline to 0.61 at 6 months and 0.59 at 12 months, representing statistically significant reductions of 0.75 and 0.77 medications respectively (p < 0.001 for both).
At 12 months, use of anti-diabetic medications declined from 17.8% to 12.7%, insulin use from 2.6% to 1.4%, anti-hypertensives from 30.9% to 20.8%, and lipid-lowering therapy from 22% to 18.8%.
All procedures were performed by a single experienced endoscopist using a U-shaped suturing pattern in a retrospective cohort at Singapore General Hospital.
The findings support the role of ESG in promoting pharmacologic de-escalation alongside weight loss in patients with obesity-related comorbidities.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

The management of obesity is often complicated by associated comorbidities such as type 2 diabetes, hypertension and hyperlipidaemia—all of which contribute to significant polypharmacy. High pill burden is linked to reduced adherence, increased healthcare costs, and lower quality of life. While Endoscopic Sleeve Gastroplasty (ESG) has been established as a minimally invasive intervention for weight loss, its impact on medication use remains underexplored. This study aims to evaluate changes in medication burden following ESG in a real-world cohort, with a focus on the potential for pharmacological de-escalation alongside weight loss.

Aims & Methods

We conducted a retrospective review of 236 patients who underwent ESG at Singapore General Hospital between November 2020 and December 2025. All procedures were performed by a single experienced endoscopist using a U-shaped suturing pattern. The primary outcome was change in medication burden, defined as the total number of prescribed medications at baseline, 6 months, and 12 months following ESG. Data on medication count were collected from electronic medical records, including all chronic medications prescribed for obesity-related comorbidities.

Results

At baseline, 17.8% of patients were on one or more oral anti-diabetic medications, 2.6% were on insulin, 30.9% were taking antihypertensives, and 22% were on lipid-lowering therapy. At 6 months post-ESG, the proportion of patients on anti-diabetic medications decreased to 15.2%, and insulin use dropped slightly to 2.1%. Anti-hypertensive use declined to 20.8%, and lipid-lowering therapy was reduced to 17.1%. By 12 months, further reductions were observed: 12.7% of patients remained on anti-diabetic medications, only 1.4% were on insulin, and use of anti-hypertensives and lipid-lowering agents fell to 20.8% and 18.8%, respectively.
The total number of medications per patient decreased significantly over time. At baseline, patients were on an average of 1.36 medications targeting diabetes, hypertension, and hyperlipidemia. This declined to 0.61 medications at 6 months and 0.59 at 12 months, corresponding to mean reductions of 0.75 (95% CI: 0.42–1.07, p < 0.001) and 0.77 (95% CI: 0.46–1.08, p < 0.001), respectively. These reductions were consistent across all major cardiometabolic drug classes.

Conclusion

In addition to driving meaningful weight loss, ESG contributes to a measurable reduction in medication burden for obesity-related comorbidities. These findings support the broader role of ESG in promoting pharmacologic de-escalation, potentially improving long-term adherence and quality of life in patients with obesity.

Disclosure

NIL

Conference

UEG Week Berlin 2025

Topics

Oesophagus

Submission format

Abstract

Session

OESOPHAGEAL, GASTRIC AND DUODENAL (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Visceral thrombosis in pancreatic disorders: Incidence and treatment algorithms

Peter Hegyi

POLYDEEP ADVANCE 3: MULTICENTRE RANDOMIZED CONTROLLED TRIAL COMPARING THE POLYDEEP-ASSISTED COLONOSCOPY WITH CONVENTIONAL COLONOSCOPY

Joaquín Cubiella

Incidence and management of bile duct injuries

Dieter Broering

USE OF NONINVASIVE TESTS (NITS) TO DIAGNOSE AND FOLLOW METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) WITH LIVER FIBROSIS PATIENTS TREATED WITH RESMETIROM

Jörn Schattenberg

Advances in PBC Management: A Simple Approach (Gilead) (Complete Session)

Maria-Carlota Londoño

AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER (ARFID) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: IMPACT ON BODY COMPOSITION AND QUALITY OF LIFE

Lígia Yukie Sassaki

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Visceral thrombosis in pancreatic disorders: Incidence and treatment algorithms

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.